Roivant Sciences Ltd
NASDAQ:ROIV
Relative Value
The Relative Value of one ROIV stock under the Base Case scenario is 1.25 USD. Compared to the current market price of 11.11 USD, Roivant Sciences Ltd is Overvalued by 89%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
ROIV Competitors Multiples
Roivant Sciences Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
BM |
Roivant Sciences Ltd
NASDAQ:ROIV
|
8.9B USD | 72.6 | 2 | -2.5 | -2.4 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
698B USD | 20.4 | 133.1 | 60.2 | 69.1 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 17.1 | 47.4 | 34.7 | 37.8 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | 9 733.7 | 1 771.8 | 4 320.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
352.2B USD | 4.3 | 8.7 | 11.6 | 15.3 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 5.5 | 910.3 | 45.2 | 88.3 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
186.7B GBP | 5.1 | 39.2 | 140.6 | 225.5 | ||
CH |
Novartis AG
SIX:NOVN
|
182.5B CHF | 4.3 | 13.4 | 9.8 | 16.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
176.8B CHF | 3 | 15.4 | 8.8 | 10.4 |